Baytugan Nart Zafer, Kandemir Hasan Caglayan, Dağlı Muharrem, Bezgin Tahir, Çelik Aziz İnan, Zengin Ahmet, Çağdaş Metin
Department of Cardiology, Gebze State Hospital, Gebze.
Kocaeli State Hospital, Kocaeli, Turkey.
Acta Cardiol Sin. 2025 Jan;41(1):138-147. doi: 10.6515/ACS.202501_41(1).20241024A.
The systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are novel inflammation-related markers calculated based on peripheral blood count. Data on biomarkers for the prognosis of peripheral artery disease (PAD) are limited. We aimed to evaluate the impact of these four inflammation-related biomarkers on mid-term restenosis and mortality rates in PAD patients.
This retrospective single-center study was conducted at a tertiary hospital between March 2020 and May 2023. Patients admitted to our catheterization laboratory for percutaneous coronary intervention for PAD were enrolled. The primary endpoint was all-cause mortality, and the secondary endpoint was restenosis.
A total of 418 participants were enrolled, including 211 in the study group and 207 in the control group. The average follow-up period was 20.80 ± 10.11 months. During the follow-up period, 39 patients (18.5%) died and restenosis occurred in 37 patients (17.5%). The mortality rate was significantly higher in the patients with high SII, SIRI, NLR, and PLR (p = 0.001, p = 0.001, p = 0.001, and p = 0.001, respectively). No significant correlations were found between SII, SIRI, NLR, PLR, and restenosis (all p > 0.05). In multivariate logistic regression analysis, only NLR was found to be an independent risk factor for mortality [(odds ratio) 6.91, 95% confidence interval: 3.18-14.99, p = 0.001].
The SII, SIRI, NLR, and PLR were higher in non-survivors, and NLR was independently associated with mortality in patients with PAD.
全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）、中性粒细胞与淋巴细胞比值（NLR）以及血小板与淋巴细胞比值（PLR）是基于外周血细胞计数计算得出的新型炎症相关标志物。关于外周动脉疾病（PAD）预后生物标志物的数据有限。我们旨在评估这四种炎症相关生物标志物对PAD患者中期再狭窄和死亡率的影响。
这项回顾性单中心研究于2020年3月至2023年5月在一家三级医院进行。纳入因PAD接受经皮冠状动脉介入治疗而入住我院导管实验室的患者。主要终点是全因死亡率，次要终点是再狭窄。
共纳入418名参与者，其中研究组211名，对照组207名。平均随访期为20.80±10.11个月。随访期间，39名患者（占18.5%）死亡，37名患者（占17.5%）发生再狭窄。SII、SIRI、NLR和PLR升高的患者死亡率显著更高（分别为p = 0.001、p = 0.001、p = 0.001和p = 0.001）。未发现SII、SIRI、NLR、PLR与再狭窄之间存在显著相关性（所有p>0.05）。在多因素逻辑回归分析中，仅发现NLR是死亡率的独立危险因素【（比值比）6.91，95%置信区间：3.18 - 14.99，p = 0.001】。
非存活者的SII、SIRI、NLR和PLR较高，且NLR与PAD患者的死亡率独立相关。
